Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 3/2004

01-06-2004 | Letter

Difference in treatment response of osteoarthritic pain in the hip and knee

Authors: Sigrun Chrubasik, Andrew Black

Published in: Clinical Rheumatology | Issue 3/2004

Login to get access

Excerpt

We were interested to read the report in Clinical Rheumatology by Ernst regarding Avocado–soybean unsaponifiables for osteoarthritis (ASU). …
Literature
1.
Ernst E (2003) Avocado–soybean unsaponifiables (ASU) for osteoarthritis – a systematic review. Clin Rheumatol 22:285–288CrossRefPubMed
2.
Blotman F, Maheu E, Wulwik A, Caspard H, Lopez A (1997) Efficacite et tolerance des insaponifiables d’avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques. Essai prospectif, multicentrique, de trois mois, randomise, en double insu, controle versus placebo. Rev Rhum Mal Osteoartic 41:81–91
3.
Maheu E, Mazieres B, Valat JP et al. (1998) Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoartbritis of the knee and hip. A prospective, randomized, double-blind study, placebo-controlled, rnulticenter clinical trial with six months treatment period and a two-month follow-up demonstrating persistent effect. Arthritis Rheum 41:81–91CrossRefPubMed
4.
Chrubasik S, Thanner J, Künzel O, Conradt C, Black A, Pollak S (2002) Comparison of outcome measures during treatment with the proprietary Harpagophytum extract Doloteffin in patients with pain in the lower back, knee or hip. Phytomedicine 9:181–94PubMed
5.
Germain BF, Dillard CO, Levi L et al. (1985) A placebo-controlled study of diclofenac sodium for the treatment of osteoartbritis of the hip and knee. Curr Ther Res 37:259–268
Metadata
Title
Difference in treatment response of osteoarthritic pain in the hip and knee
Authors
Sigrun Chrubasik
Andrew Black
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2004
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-0868-9

Other articles of this Issue 3/2004

Clinical Rheumatology 3/2004 Go to the issue

Case Report

Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis

Original Article

Diagnostic value of antiagalactosyl IgG antibodies in rheumatoid arthritis

Original Article

Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus

Letter to the Editor

Lateral epicondylitis with marked soft tissue swelling in spondyloarthritis

Case Report

A case of scleroderma spectrum disorder with anticentriole antibody and pulmonary hypertension

Original Article

Respiratory muscle strength but not BASFI score relates to diminished chest expansion in ankylosing spondylitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits